Evidence map›Paper›PMID 31526383›Full record

ArticleJournal of nanobiotechnology2019

A novel biotinylated nanobody-based blocking ELISA for the rapid and sensitive clinical detection of porcine epidemic diarrhea virus.

Zhiqian Ma, Tianyu Wang, Zhiwei Li, Xuyang Guo, Yangsheng Tian, Yang Li, Shuqi Xiao

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Frontiers in cellular and infection microbiology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Diagnosis and Stratification ofFrontiers in cellular and infection microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhiqian MaCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China.
Tianyu WangCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China.
Zhiwei LiCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China.
Xuyang GuoCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China.
Yangsheng TianCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China.
Yang LiCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China.
Shuqi XiaoCollege of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China. xiaoshuqi@nwsuaf.edu.cn.
Northwest A&F University · CN

Funding

CSRD VA 1Key R&D Project in Shaanxi Province of China 2019NY-076National Key R&D Projects 2017YFD0500605National Key R&D Projects 2017YFD0501102
6 · The paper itself

Abstract

backgroundPorcine epidemic diarrhea virus (PEDV), which is characterized by severe watery diarrhea, vomiting, dehydration and a high mortality rate in piglets, leads to enormous economic losses to the pork industry and remains a large challenge worldwide. Thus, a rapid and reliable method is required for epidemiological investigations and to evaluate the effect of immunization. However, the current diagnostic methods for PEDV are time-consuming and very expensive and rarely meet the requirements for clinical application. Nanobodies have been used in the clinic to overcome these problems because of the advantages of their easy expression and high level of stability. In the present work, a novel biotinylated nanobody-based blocking ELISA (bELISA) was developed to detect anti-PEDV antibodies in clinical pig serum.

resultsUsing phage display technology and periplasmic extraction ELISA (PE-ELISA), anti-PEDV N protein nanobodies from three strains of PEDV were successfully isolated after three consecutive rounds of bio-panning from a high quality phage display VHH library. Then, purified Nb2-Avi-tag fusion protein was biotinylated in vitro. A novel bELISA was subsequently developed for the first time with biotinylated Nb2. The cutoff value for bELISA was 29.27%. One hundred and fifty clinical serum samples were tested by both newly developed bELISA and commercial kits. The sensitivity and specificity of bELISA were 100% and 93.18%, respectively, and the coincidence rate between the two methods was 94%.

conclusionsIn brief, bELISA is a rapid, low-cost, reliable and useful nanobody-based tool for the serological evaluation of current PEDV vaccines efficacy and indirect diagnosis of PEDV infection.

Indexed as

AnimalsAntibodies, ViralBiotinylationCamelusCoronavirus InfectionsEnzyme-Linked Immunosorbent AssayImmunizationMalePorcine epidemic diarrhea virusSensitivity and SpecificitySingle-Domain AntibodiesSwineAntibodies, ViralSingle-Domain AntibodiesBiotinylated-nanobodyBlocking ELISAPEDV

Identifiers

PMID31526383
PMCPMC6745792
OpenAlexW2974814036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.